NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $44.51 -1.30 (-2.84 %) (As of 01/26/2020 06:07 AM ET) Add Compare Today's Range$44.25Now: $44.51▼$46.3450-Day Range$44.51MA: $46.36▼$48.8652-Week Range$42.48Now: $44.51▼$64.48Volume533,510 shsAverage Volume398,947 shsMarket Capitalization$2.23 billionP/E Ratio4.14Dividend YieldN/ABeta1.47 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ARNA Previous Symbol CUSIP04004710 CIK1080709 Webhttp://www.arenapharm.com/ Phone858-453-7200Debt Debt-to-Equity Ratio0.04 Current Ratio21.90 Quick Ratio21.90Price-To-Earnings Trailing P/E Ratio4.14 Forward P/E Ratio5.45 P/E GrowthN/A Sales & Book Value Annual Sales$17.97 million Price / Sales124.12 Cash FlowN/A Price / Cash FlowN/A Book Value$12.27 per share Price / Book3.63Profitability EPS (Most Recent Fiscal Year)($2.95) Net Income$-29,400,000.00 Net Margins68.29% Return on Equity42.34% Return on Assets39.11%Miscellaneous Employees194 Outstanding Shares50,110,000Market Cap$2.23 billion Next Earnings Date2/25/2020 (Estimated) OptionableOptionable Receive ARNA News and Ratings via Email Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ARNA Rates by TradingView Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions What is Arena Pharmaceuticals' stock symbol? Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA." When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work? Arena Pharmaceuticals shares reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.32) by $0.14. The biopharmaceutical company earned $1.35 million during the quarter, compared to the consensus estimate of $2.06 million. Arena Pharmaceuticals had a net margin of 68.29% and a return on equity of 42.34%. The company's revenue was down 62.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.70) earnings per share. View Arena Pharmaceuticals' Earnings History. When is Arena Pharmaceuticals' next earnings date? Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Arena Pharmaceuticals. What price target have analysts set for ARNA? 5 analysts have issued 12-month price objectives for Arena Pharmaceuticals' stock. Their forecasts range from $51.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $67.25 in the next year. This suggests a possible upside of 51.1% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals. What is the consensus analysts' recommendation for Arena Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arena Pharmaceuticals. What are Wall Street analysts saying about Arena Pharmaceuticals stock? Here are some recent quotes from research analysts about Arena Pharmaceuticals stock: 1. According to Zacks Investment Research, "Arena Pharmaceuticals is focused on developing its two pipeline candidates — etrasimod and olorinab. The company out-licensed ralinepag to United Therapeutics and the fund is being used to support continuation of clinical development of other candidates. Meanwhile, the company’s decision to sell its manufacturing operations and out-licensing of Belviq to focus on the pipeline is prudent in our view. However, Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have a negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in the market, due to competition." (12/30/2019) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $62 PT. Arena today reported 1Q financials and provided an update on its clinical programs, including details on the etrasimod Ph3 trial design in ulcerative colitis (UC) that is still expected to initiate mid-year. We think the planned Ph3 UC program is strategically designed to expedite enrollment and support a differentiated commercial profile for etrasimod. We continue to believe IBD represents a large and growing market, and etrasimod is well-positioned in UC with potential to expand into other I&I indications due to its safety profile." (5/8/2019) Has Arena Pharmaceuticals been receiving favorable news coverage? News articles about ARNA stock have been trending extremely negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Arena Pharmaceuticals. Who are some of Arena Pharmaceuticals' key competitors? Some companies that are related to Arena Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Cytokinetics (CYTK), Canopy Growth (CGC), Advanced Micro Devices (AMD), Micron Technology (MU), Inovio Pharmaceuticals (INO), ZIOPHARM Oncology (ZIOP), Zynerba Pharmaceuticals (ZYNE), Exelixis (EXEL), XOMA (XOMA) and AT&T (T). Who are Arena Pharmaceuticals' key executives? Arena Pharmaceuticals' management team includes the folowing people: Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50) Who are Arena Pharmaceuticals' major shareholders? Arena Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.44%), AdvisorShares Investments LLC (0.07%), Assenagon Asset Management S.A. (0.05%), Strs Ohio (0.05%), Bowling Portfolio Management LLC (0.03%) and Hexavest Inc. (0.02%). Company insiders that own Arena Pharmaceuticals stock include Jayson Donald Alexander Dallas, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Institutional Ownership Trends for Arena Pharmaceuticals. Which major investors are selling Arena Pharmaceuticals stock? ARNA stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC and Exane Derivatives. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Jayson Donald Alexander Dallas, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Insider Buying and Selling for Arena Pharmaceuticals. Which major investors are buying Arena Pharmaceuticals stock? ARNA stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, AdvisorShares Investments LLC, Assenagon Asset Management S.A., Hexavest Inc., New York State Teachers Retirement System, Strs Ohio and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Arena Pharmaceuticals. How do I buy shares of Arena Pharmaceuticals? Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Arena Pharmaceuticals' stock price today? One share of ARNA stock can currently be purchased for approximately $44.51. How big of a company is Arena Pharmaceuticals? Arena Pharmaceuticals has a market capitalization of $2.23 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.View Additional Information About Arena Pharmaceuticals. What is Arena Pharmaceuticals' official website? The official website for Arena Pharmaceuticals is http://www.arenapharm.com/. How can I contact Arena Pharmaceuticals? Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected] MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 375 (Vote Outperform)Underperform Votes: 429 (Vote Underperform)Total Votes: 804MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: What is included in the gross domestic product?
